Hologic (NASDAQ:HOLX) Receives New Coverage from Analysts at Stephens

Stephens started coverage on shares of Hologic (NASDAQ:HOLX) in a report published on Thursday, Marketbeat.com reports. The brokerage issued an overweight rating and a $87.00 target price on the medical equipment provider’s stock.

HOLX has been the topic of several other reports. StockNews.com raised shares of Hologic from a hold rating to a buy rating in a research report on Friday, May 3rd. Evercore ISI boosted their price objective on shares of Hologic from $76.00 to $78.00 and gave the stock an in-line rating in a research report on Thursday, April 4th. JPMorgan Chase & Co. raised their target price on shares of Hologic from $85.00 to $91.00 and gave the company an overweight rating in a report on Friday, May 3rd. Argus increased their price target on shares of Hologic from $89.00 to $95.00 and gave the company a buy rating in a research report on Thursday, May 9th. Finally, Needham & Company LLC reaffirmed a buy rating and issued a $90.00 target price on shares of Hologic in a research note on Friday, May 3rd. Five equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of Moderate Buy and a consensus target price of $85.73.

Hologic Trading Up 0.1 %

NASDAQ HOLX opened at $74.25 on Thursday. The company’s 50-day simple moving average is $74.32 and its two-hundred day simple moving average is $74.32. The company has a debt-to-equity ratio of 0.52, a quick ratio of 3.29 and a current ratio of 3.97. The company has a market capitalization of $17.33 billion, a price-to-earnings ratio of 37.88, a price-to-earnings-growth ratio of 2.47 and a beta of 1.00. Hologic has a one year low of $64.02 and a one year high of $82.45.

Hologic (NASDAQ:HOLX) last released its earnings results on Thursday, May 2nd. The medical equipment provider reported $1.03 EPS for the quarter, topping analysts’ consensus estimates of $0.98 by $0.05. The company had revenue of $1.02 billion during the quarter, compared to analysts’ expectations of $1 billion. Hologic had a net margin of 11.78% and a return on equity of 18.91%. Hologic’s revenue for the quarter was down .8% on a year-over-year basis. During the same period last year, the business earned $1.06 EPS. Equities analysts forecast that Hologic will post 4.08 EPS for the current fiscal year.

Hedge Funds Weigh In On Hologic

A number of hedge funds have recently made changes to their positions in the stock. McGlone Suttner Wealth Management Inc. acquired a new stake in Hologic during the fourth quarter worth about $27,000. iA Global Asset Management Inc. acquired a new position in Hologic during the first quarter valued at approximately $37,000. Massmutual Trust Co. FSB ADV increased its position in shares of Hologic by 69.4% in the fourth quarter. Massmutual Trust Co. FSB ADV now owns 554 shares of the medical equipment provider’s stock worth $40,000 after acquiring an additional 227 shares in the last quarter. Allworth Financial LP increased its position in shares of Hologic by 39.3% in the fourth quarter. Allworth Financial LP now owns 634 shares of the medical equipment provider’s stock worth $45,000 after acquiring an additional 179 shares in the last quarter. Finally, Mather Group LLC. purchased a new position in shares of Hologic in the 1st quarter valued at $48,000. Institutional investors and hedge funds own 94.73% of the company’s stock.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.